CN114869977B - Application of lung cough in preparation of product for preventing and treating breast cancer - Google Patents

Application of lung cough in preparation of product for preventing and treating breast cancer Download PDF

Info

Publication number
CN114869977B
CN114869977B CN202210310305.7A CN202210310305A CN114869977B CN 114869977 B CN114869977 B CN 114869977B CN 202210310305 A CN202210310305 A CN 202210310305A CN 114869977 B CN114869977 B CN 114869977B
Authority
CN
China
Prior art keywords
breast cancer
cough
lung
cells
product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202210310305.7A
Other languages
Chinese (zh)
Other versions
CN114869977A (en
Inventor
杨珏
李艳梅
张知音
邱剑飞
赵鹏
韦学耐
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Key Laboratory of Natural Product Chemistry of Guizhou Academy of Sciences
Original Assignee
Key Laboratory of Natural Product Chemistry of Guizhou Academy of Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Key Laboratory of Natural Product Chemistry of Guizhou Academy of Sciences filed Critical Key Laboratory of Natural Product Chemistry of Guizhou Academy of Sciences
Priority to CN202210310305.7A priority Critical patent/CN114869977B/en
Publication of CN114869977A publication Critical patent/CN114869977A/en
Application granted granted Critical
Publication of CN114869977B publication Critical patent/CN114869977B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/539—Scutellaria (skullcap)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/51—Gentianaceae (Gentian family)
    • A61K36/515—Gentiana
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/74—Rubiaceae (Madder family)
    • A61K36/748—Oldenlandia or Hedyotis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/904—Stemonaceae (Stemona family), e.g. croomia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The invention provides application of lung cough in preparation of a product for preventing and treating breast cancer, and belongs to the technical field of biological pharmacy. The invention discovers for the first time that the lung power cough can effectively treat the breast cancer, and the lung power cough has the effects of inhibiting the activity of breast cancer cells, inhibiting the proliferation of the breast cancer cells, promoting the apoptosis of the breast cancer cells and changing the morphology of the breast cancer cells, thereby achieving the effect of treating the breast cancer. The lung strength cough has the advantages that the lung strength cough can inhibit the proliferation of breast cancer cells, has concentration dependence, has obvious influence on the cell cycle of human breast cancer, can block the cell cycle of the breast cancer from the S phase, and has more obvious blocking when the medicine concentration is higher.

Description

Application of lung cough in preparation of product for preventing and treating breast cancer
Technical Field
The invention belongs to the technical field of biological pharmacy, and particularly relates to application of lung cough in preparation of a product for preventing and treating breast cancer.
Background
Lung power cough is a Chinese patent medicine, and the main components comprise radix scutellariae, radix peucedani, radix stemonae, safflower gentian, phoenix tree root, oldenlandia diffusa and Hongguan medicine. The lung power cough circulating in the market at present comprises two medicinal dosage forms of a lung power cough mixture and a lung power cough capsule, wherein the lung power cough capsule contains yellow brown to brown powder and particles, and is bitter in taste. The lung-power cough has the clinical effects of relieving cough and asthma, clearing away heat and toxic materials, guiding qi downward and eliminating phlegm, and is suitable for patients with cough, asthma and excessive phlegm, unsmooth breathing, acute and chronic bronchitis, emphysema and other symptoms. The prior art does not describe the technical content of lung cough related to the treatment or prevention of breast cancer.
Disclosure of Invention
In view of this, the present invention aims to provide an application of cough with lung strength in preparing a product for preventing and treating breast cancer, which can inhibit the activity of breast cancer cells, inhibit the proliferation of breast cancer cells, promote the apoptosis of breast cancer cells, and change the morphology of breast cancer cells, thereby achieving the effect of treating breast cancer.
In order to achieve the above object, the present invention provides the following technical solutions:
the invention provides application of lung cough in preparing a product for preventing and treating breast cancer.
The invention also provides application of the lung cough in preparing a product for inhibiting breast cancer cell viability.
The invention also provides application of the lung cough in preparing a product for inhibiting breast cancer cell proliferation.
The invention also provides application of the lung cough in preparation of a product for promoting breast cancer cell apoptosis.
Preferably, the product comprises a medicament.
Preferably, the lung power cough comprises a lung power cough mixture and a lung power cough capsule.
Preferably, the medicament comprises injection, powder, tablets, granules, capsules, solutions, emulsions, suspensions, sprays, aerosols, powders, ointments, plasters, patches, suppositories, drops or dripping pills.
The invention also provides a medicine for preventing and treating breast cancer, which comprises the effective components of cough with lung force or cough with lung force.
The invention also provides a preparation method of the medicine, which comprises the following steps: the lung cough is directly prepared into a medicinal preparation for preventing and treating breast cancer, or the lung cough and other medicaments for preventing and treating breast cancer are compounded to prepare a compound medicinal preparation, or the effective component of the lung cough and a pharmaceutically acceptable carrier are prepared into the medicinal preparation for preventing and treating breast cancer
The invention has the beneficial effects that:
the invention provides application of lung cough in preparation of a product for preventing and treating breast cancer for the first time, and particularly relates to the application of the lung cough in preparation of a product for preventing and treating breast cancer, which can inhibit the activity of breast cancer cells, inhibit the proliferation of the breast cancer cells, promote the apoptosis of the breast cancer cells and change the form of the breast cancer cells, so that the effect of effectively treating the breast cancer is achieved. In addition, the lung power cough has concentration dependence for inhibiting the proliferation of breast cancer cells, the influence of the lung power cough on the cell cycle of human breast cancer is obvious, the cell cycle of the breast cancer can be blocked in the S phase, and the blocking is more obvious when the medicine concentration is higher.
The invention discovers that the lung cough has potential value in the aspect of preparing the medicine for preventing and treating the breast cancer or the medicine preparation for inhibiting the proliferation of the breast cancer cells for the first time. The lung-strength cough is a Chinese patent medicine which is already used in clinic, can be directly applied to a human body without clinical safety assessment, has good application prospect, and can quickly improve the market share of the product.
Drawings
FIG. 1 shows the effect of lung strength cough capsules of different concentrations on the morphology of human breast cancer cells MDA-MB-231.
Fig. 2 is a graph of the effect of different concentrations of lung strength cough capsules on the growth of human breast cancer cells MDA-MB-231, where P <0.05 indicates P <0.01.
Fig. 3 is the detection of the number of clones formed by the lung strength cough capsule with different concentrations after acting on human breast cancer cell MDA-MB-231 cells for 24h, which indicates that P is less than 0.01.
FIG. 4 shows that the lung-strength cough capsules with different concentrations act on human breast cancer cells MDA-MB-231 for 24h and 48h, then the apoptosis is detected by a flow cytometer, P is less than 0.01 compared with NC group, and P is less than 0.01 compared with 24 h.
FIG. 5 is a test of Hoechst 33258 staining after lung-strength cough capsules with different concentrations act on human breast cancer MDA-MB-231 cells for 24 h.
FIG. 6 shows that the lung-strength cough capsules with different concentrations act on human breast cancer MDA-MB-231 cells for 24h and the period is detected by a flow cytometer after 48 h.
FIG. 7 shows tumor volume growth of different groups of 4T1 tumor-bearing mice; wherein indicates P <0.01.
FIG. 8 shows the tumor weights of different groups of 4T1 tumor-bearing mice; wherein indicates P <0.05.
Detailed Description
The invention provides application of lung cough in preparing a product for preventing and treating breast cancer. The invention also provides application of the lung cough in preparing products for inhibiting breast cancer cell activity, inhibiting breast cancer cell proliferation and promoting breast cancer cell apoptosis.
The specific source of the cough with lung force is not particularly limited in the invention, and any commercially available product which is conventional in the art can be adopted, and in the invention, the cough with lung force preferably comprises a cough mixture and a cough capsule, and the product preferably comprises a medicament. The type of breast cancer cell in the present invention is not particularly limited, and preferably includes human breast cancer cell MCF-7, MDA-MB-231, MDA-MB-468 and mouse breast cancer cell 4T1. The sources of the human breast cancer cells MCF-7, MDA-MB-231, MDA-MB-468 and the mouse breast cancer cell 4T1 are not particularly limited, the cells can be purchased commercially and can also be frozen and stored in a laboratory, and in the embodiment of the invention, the human breast cancer cells MCF-7, MDA-MB-231, MDA-MB-468 and the mouse breast cancer cell 4T1 are all retained in a chemical key laboratory of a natural product of Chinese academy of sciences in Guizhou province.
In the present invention, the pharmaceutical preparation preferably includes injection, powder, tablet, granule, capsule, solution, emulsion, suspension, spray, aerosol, powder spray, ointment, plaster, patch, suppository, drop or dripping pill. The invention has no special requirements on the auxiliary materials of each preparation formulation, and the preparation can adopt the conventional auxiliary materials when the preparation formulation is prepared in the field.
The invention also provides a medicament for preventing and treating breast cancer, which comprises the active ingredients of cough with lung strength or cough with lung strength.
The source of the lung cough, the source of the breast cancer cells, the dosage form of the medicinal preparation, auxiliary materials and the like are not specially limited. In a specific embodiment of the present invention, the main effective components for cough due to lung-heat preferably comprise scutellaria baicalensis, peucedanum root, stemona root, gentiana carthami, phoenix tree root, oldenlandia diffusa and rambutan.
The invention also provides a preparation method of the medicine, which comprises the following steps: the lung cough is directly prepared into a pharmaceutical preparation for preventing and treating breast cancer, or the lung cough and other drugs for preventing and treating breast cancer are compounded to prepare a compound pharmaceutical preparation, or the effective component of the lung cough and a pharmaceutically acceptable carrier are prepared into the pharmaceutical preparation for preventing and treating breast cancer.
In the preparation method of the pharmaceutical preparation of the present invention, the content such as adjuvants and how to prepare the pharmaceutical preparation is not described in detail, and is a routine choice in the art.
The technical solutions provided by the present invention are described in detail below with reference to examples, but they should not be construed as limiting the scope of the present invention.
Example 1
Collecting MCF-7 cells, MDA-MB-231 cells, MDA-MB-468 cells, and 4T1 cells in log phase at 6X 10 3 The density of each well is inoculated in a 96-well plate, the culture is carried out overnight, after the cells adhere to the wall, sample solutions (physiological saline solution of the effective components of the Feilke capsule (medicament after removing the capsule shell) are added with different concentrations of 0.25mg/ml, 0.5mg/ml, 1mg/ml, 2mg/ml and 4 mg/ml) for treatment, and the Feilke capsule is produced by Guizhou Jianxing pharmaceutical industry and takes the physiological saline as a control group. And after the drug acts for 72 hours, adding 10 mu l of MTT with the concentration of 5mg/ml into each hole, incubating at 37 ℃ for 4 hours, discarding the supernatant, adding 160 mu l of DMSO into each hole to dissolve, and measuring the absorbance value OD (490 nm) by using an enzyme reader after the purple crystal formazan is completely dissolved.
The calculation method of the inhibition rate comprises the following steps: inhibition = (control OD value-treatment OD value)/control OD value. Median Inhibitory Concentration (IC) 50 ) The calculating method of (2): obtaining corresponding IC by using forecast function 50 。
The results show that sample solutions with different concentrations can inhibit the activities of MCF-7 cells, MDA-MB-231 cells, MDA-MB-468 cells and 4T1 cells, and have concentration dependence, and the IC of the lung-strength cough capsule on the MCF-7 cells, the MDA-MB-231 cells, the MDA-MB-468 cells and the 4T1 cells 50 The values are 2.91. + -. 0.82mg/ml, 0.55. + -. 0.10mg/ml, 1.08. + -. 0.08mg/ml and 0.74. + -. 0.32mg/ml, respectively.
Example 2
MDA-MB-231 cells were plated at 4X 10 5 Inoculating the cells/well into a circular culture dish of 60mm, culturing, adding sample solutions (0.25 mg/ml, 0.5mg/ml, 1mg/ml, 2 mg/ml) with different concentrations (normal saline solution of effective components of pulmonal cough capsule (medicine without capsule shell) after the cells adhere to the wall, wherein the pulmonal cough capsule is prepared from Guizhou JianManufactured in the pharmaceutical industry) for 24 hours, and the normal saline is taken as a control group. The morphological changes of the cells were observed under an inverted microscope.
The results are shown in FIG. 1, where the number of cells decreased significantly with increasing drug concentration. The cell morphology is changed, and particularly, the cell morphology is changed from a long fusiform shape to a round shape at a high concentration, and the cell is swollen.
Example 3
MDA-MB-231 cells were collected in log phase at 6X 10 3 The density of each well is inoculated in a 96-well plate, the culture is carried out overnight, after the cells adhere to the wall, sample solutions (0.25 mg/ml, 0.5mg/ml, 1mg/ml and 2 mg/ml) (physiological saline solution of effective components (medicament after removing the shell of the capsule) of the lung-strength cough capsule, the lung-strength cough capsule is manufactured by Guizhou Jianxing pharmaceutical industry) with different concentrations are added for treatment, the OD 490nm is respectively measured for 0h, 24h, 48h and 72h by taking the physiological saline as a control group, and a growth curve is drawn.
As shown in FIG. 2, the sample solutions with different concentrations all inhibited the proliferation of MDA-MB-231 cells, and the growth rate of MDA-MB-231 cells gradually decreased with increasing concentration, indicating that the Feihu capsule sample solution can inhibit the proliferation of MDA-MB-231 cells and is concentration-and time-dependent.
Example 4
MDA-MB-231 cells were plated at 4X 10 5 The amount of each well is inoculated in a circular culture dish of 60mm for culture, after the cells adhere to the wall, sample solutions (0.5 mg/ml, 1mg/ml and 2 mg/ml) with different concentrations (normal saline solution of the effective components (the medicine after removing the capsule shell) of the Feilike capsule, the Feilike capsule is manufactured by Guizhou Jianxing pharmaceutical industry) are added for acting for 24h, and the normal saline is used as a control group, and the cells are digested, collected and counted. The culture was continuously cultured in a 6-well plate at 1000/well in a culture box using DMEM medium containing 5% FBS, with fresh medium being replaced every three days. After 14 days, the culture solution is discarded, PBS is washed for 2-3 times, methanol is fixed for 15min,0.1% crystal violet is stained for 15min, PBS is used for washing for 5-8 times, air drying and photographing are carried out, and the number of clones containing more than 50 cells is counted under a light microscope.
As shown in FIG. 3, the number of formed clones and the diameters of the clones were significantly decreased with the increase of the concentration of the sample solution and had a certain concentration dependence, which indicates that the Feihukong capsule sample solution can inhibit the proliferation of MDA-MB-231 cells in vitro, compared with the control group.
Example 5
MDA-MB-231 cells were plated at 4X 10 5 The amount of each cell is inoculated in a circular culture dish of 60mm for culture, after the cells adhere to the wall, sample solutions (0.5 mg/ml, 1mg/ml and 2 mg/ml) with different concentrations (physiological saline solution of the effective components (the medicine after removing the capsule shell) of the Feilike capsule, the Feilike capsule is manufactured by Guizhou Jianxing pharmaceutical industry) are added for acting for 24 hours or 48 hours, and then the cells are collected, and the physiological saline is taken as a control group. Washing with PBS 3 times, adding 500 μ l 1 XBinding Buffer to resuspend cells, adding 5 μ l Annexin V-FITC and 10 μ l propidium iodide, incubating at room temperature in dark for 15min, and detecting with flow cytometer to calculate the apoptosis rate.
As shown in FIG. 4, the sample solutions with different concentrations induced apoptosis of human breast cancer MDA-MB-231 and were concentration-dependent compared to the control group.
Example 6
Soaking clean cover glass in 70% ethanol for 5min or longer, washing with sterilized PBS for three times in the biological safety cabinet, and washing with cell culture solution for one time. The coverslip was placed in a 6-well plate and MDA-MB-231 cells were plated at 4X 10 5 One/well was planted in a 60mm round petri dish and incubated overnight. The next day after the cells adhered to the wall, the supernatant was discarded, and sample solutions (0.5 mg/ml, 1mg/ml, 2 mg/ml) of different concentrations (physiological saline solution of the effective component of feilike capsules (drug without capsule shell) manufactured by Guizhou Jianxing pharmaceutical industry) were added, with physiological saline as the control group. After 24h of action, the culture medium is completely aspirated, 0.5mL of stationary liquid is added, and the solution is fixed for 10min. The solution was washed twice with PBS, shaken by hand for 3min each time, and the solution was aspirated. 0.5mL of Hoechst 33258 staining solution is added for staining for 5min. During which time the hand is shaken several times. After staining was completed, the cells were washed twice with PBS for 3min each time, and the liquid was aspirated. Dropping a drop of anti-fluorescence quenching mounting fluid on the glass slide, and covering the glass slide with the cellsThe cells are allowed to contact the mounting solution, avoiding air bubbles as much as possible. And (5) observing and photographing by an inverted fluorescence microscope.
As shown in FIG. 5, compared with the control group, the sample solutions with different concentrations can induce apoptosis, and the cell nuclei of the apoptotic cells are densely and densely stained or are densely stained in a broken block shape.
Example 7
MDA-MB-231 cells were plated at 4X 10 5 The amount of each hole is inoculated in a circular culture dish of 60mm for culture, after the cells adhere to the wall, sample solutions (0.5 mg/ml, 1mg/ml and 2 mg/ml) with different concentrations (physiological saline solution of the effective components (the medicine after removing the capsule shell) of the lung-strength cough capsule, and the lung-strength cough capsule is manufactured by Guizhou Jianxing pharmaceutical industry) are added for 24 hours or 48 hours, and then the cells are collected. Centrifuge at 1000rpm for 5min, wash once with pre-chilled PBS, resuspend cells with 70% pre-chilled ethanol, and fix overnight at-20 ℃. Centrifuging at 1000rpm for 5min, discarding the supernatant, washing with precooled PBS once, centrifuging at 1000rpm for 5min, and collecting the cells. The cells were resuspended in 500. Mu.l PBS, 5. Mu.l RNase A, 25. Mu.l PI and 1000.25. Mu.l Triton X were added, mixed, centrifuged at 1000rpm for 5min, the dye was discarded, resuspended in 200. Mu.l PBS and analyzed for cell cycle using flow cytometry.
The results are shown in fig. 6, the sample solutions with different concentrations have obvious effects on the human breast cancer MDA-MB-231 cycle at 24h and 48h, and block the cell cycle in the S phase, and the blocking is more obvious when the concentration of the drug is higher.
Example 8
Recovering mouse 4T1 breast cancer cell, culturing, and making into 1 × 10 6 one/mL of cell suspension, then the second papillary fat pad on the right side of each mouse was injected with 50 μ L of cell suspension subcutaneously. After 7 days, mice were randomly divided into 4 groups of 8 mice each. The dosing regimen for each group of mice was: negative control group: perfusing with normal saline once a day; low dose test group (feiku capsule-L): the medicine is administered by gastric lavage at 468mg/kg once a day; middle dose experimental group (lung power cough capsule-M): the drug is administrated by stomach irrigation at 936mg/kg once a day; high dose test group (feilke capsule-H): 1872mg/kg once daily until the mice are sacrificed. In the morning, afternoon and evening of each dayThe diet, spirit and the like of the mice were observed 1 time each. The lung-power cough capsule is purchased from Guizhou Jianxing pharmaceutical industry Co. Tumor volumes were measured with a vernier caliper every 48h starting the first day after dosing and the results are shown in figure 7. 24h after the last dose, mice were sacrificed and tumors were weighed and the results are shown in FIG. 8.
As can be seen from figures 7 and 8, the lung-strength cough capsule can obviously reduce the tumor volume of tumor-bearing mice and reduce the tumor weight.
In the above examples of the invention, each experiment was independently repeated three times, all data were expressed as mean ± SD, student's t-test was performed using GraphPad Prism 7, P <0.05 was considered statistically significant.
The foregoing is only a preferred embodiment of the present invention, and it should be noted that, for those skilled in the art, various modifications and amendments can be made without departing from the principle of the present invention, and these modifications and amendments should also be considered as the protection scope of the present invention.

Claims (7)

1. Application of lung power cough in preparing products for preventing and treating breast cancer.
2. Application of lung cough in preparing product for inhibiting breast cancer cell activity is provided.
3. Application of lung cough in preparing product for inhibiting breast cancer cell proliferation is provided.
4. Application of lung cough in preparing product for promoting apoptosis of breast cancer cells is provided.
5. The use according to any one of claims 1 to 4, wherein the product is a medicament.
6. The use according to any one of claims 1 to 4, wherein the cough due to lung force comprises a cough mixture and a cough due to lung force capsule.
7. The use of claim 5, wherein the medicament comprises an injection, a powder, a tablet, a granule, a solution, an emulsion, a spray, an ointment, a plaster, a patch, a suppository or a drop pill.
CN202210310305.7A 2022-03-28 2022-03-28 Application of lung cough in preparation of product for preventing and treating breast cancer Active CN114869977B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210310305.7A CN114869977B (en) 2022-03-28 2022-03-28 Application of lung cough in preparation of product for preventing and treating breast cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202210310305.7A CN114869977B (en) 2022-03-28 2022-03-28 Application of lung cough in preparation of product for preventing and treating breast cancer

Publications (2)

Publication Number Publication Date
CN114869977A CN114869977A (en) 2022-08-09
CN114869977B true CN114869977B (en) 2023-04-14

Family

ID=82667828

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202210310305.7A Active CN114869977B (en) 2022-03-28 2022-03-28 Application of lung cough in preparation of product for preventing and treating breast cancer

Country Status (1)

Country Link
CN (1) CN114869977B (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109692291A (en) * 2019-03-05 2019-04-30 贵州健兴药业有限公司 Lung power cough mixture medicinal extract and application thereof and method of quality control

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8858953B2 (en) * 2011-05-09 2014-10-14 Yu-Hwa Peter Sheng Herbal composition for treating cancer
CN106668753A (en) * 2015-11-08 2017-05-17 银川上河图新技术研发有限公司 Hui-nationality traditional Chinese medicine toad pills for treating breast cancer and preparation method thereof
CN111840358B (en) * 2020-09-02 2021-10-22 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) Application of jingulian capsule in preparing anti-breast cancer medicine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109692291A (en) * 2019-03-05 2019-04-30 贵州健兴药业有限公司 Lung power cough mixture medicinal extract and application thereof and method of quality control

Also Published As

Publication number Publication date
CN114869977A (en) 2022-08-09

Similar Documents

Publication Publication Date Title
WO2013071727A1 (en) Anti-tumor traditional chinese medical composition
CN111840358B (en) Application of jingulian capsule in preparing anti-breast cancer medicine
CN103505454A (en) Alpha-tubulin inhibitor and application thereof
CN114869977B (en) Application of lung cough in preparation of product for preventing and treating breast cancer
CN100381434C (en) Emblic leafflower fruit extract possessing anticancer, antibiotic actions and its manufacturing method of traditional Chinese medicine formulation
CN104666320B (en) Application of the Quzhazhigan in treating cancer medicine is prepared
Xu et al. Shionone suppresses the growth, migration and invasion of human breast cancer cells via induction of apoptosis and inhibition of MEK/ERK and STAT3 signalling pathways
CN110946948A (en) Application of Huafengdan in preparation of anti-breast cancer drugs
CN102357180A (en) Traditional Chinese medicine composite for curing cancer and preparation method and application thereof
CN106668041A (en) Application of rhizoma paridis saponin VI to preparation of anti-lung cancer drugs
CN105233150A (en) Traditional Chinese medicine composition and application thereof
CN111358804B (en) Application of Cynoside H in preparation of medicine for preventing and treating breast cancer
CN101168008B (en) Medicinal composition with tumor inhibition function and preparation method and application thereof
CN104096150B (en) Stahlianthus hainanensis (Hayata) T. L. Wu and its extract are preparing treatment and/or the application of prevention cancer drug
CN113230299A (en) Application of Jingan capsule in preparing medicine for treating breast cancer
CN106668042A (en) Application of Chonglou saponin VII to preparation of anti-lung-cancer medicament
CN109602775B (en) Application of chicory alcohol extract in preparation of anti-breast cancer drugs
CN109331031A (en) A kind of new application of chonglou saponin VII
CN104887690B (en) Application of the chonglou saponin in antitumor drug is prepared
CN110755594B (en) Application of double-ginger stomachache prescription in preparation of medicine for treating inflammatory bowel disease
CN103655600A (en) Drug composition for treating cancers, preparation method and applications
CN104083690B (en) Application of Stahlianthus involucratus (King) Craib and its extract in preparation of drugs for treating and/or preventing breast cancer
CN115245517B (en) Application of dihydrotanshinone I in preparation of breast cancer lung metastasis inhibitor
CN101690794B (en) Antitumor medicament, preparation method and quality control method
CN117243931A (en) Application of bletilla striata biphenanthrene C in preparation of medicines for inhibiting tumor metastasis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant